Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$314.77 USD

314.77
496,482

-1.73 (-0.55%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $315.11 +0.34 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Phibro (PAHC) Q4 Earnings Fall Short of Estimates, Margins Up

by Zacks Equity Research

Phibro's (PAHC) core Animal Health segment was aided by the Osprey Biotechnics acquisition despite a dismal overall performance in Q4 due to pandemic-led business disruptions.

AMN Healthcare's Advanced Mobile App to Aid Travel Clinicians

by Zacks Equity Research

AMN Healthcare's (AMN) new version of AMN Passport will benefit travel clinicians.

Allscripts Enhances Healthcare Innovation With Patent Program

by Zacks Equity Research

Allscripts (MDRX) continues to advance healthcare innovation by earning five new application patents.

Here's Why You Should Hold on to DENTSPLY (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY (XRAY) continues to gain traction from its solid focus on R&D leading to product innovation, which continues to be a key catalyst.

Here's Why You Should Invest in Fresenius Medical Stock Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services.

Veeva Systems (VEEV) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal second-quarter results are likely to reflect solid show by its segments and robust product portfolio.

Here's Why You Should Retain Cardinal Health Stock for Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.

Aparajita Dutta headshot

Buy These 5 Low Leverage Stocks to Weather Coronavirus Impact

by Aparajita Dutta

With the Q2 reporting cycle drawing to a close, investors must be eyeing stocks that exhibited solid earnings growth in the prior quarters. But choosing stocks with high debt level might be risky.

Allscripts' Collaboration to Advance Healthcare Innovation

by Zacks Equity Research

Allscripts (MDRX) partners with Israel's Sheba Medical Center to help enhance healthcare innovation with smarter technology, thereby improving patient outcomes.

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research

Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, intense competition remains a woe.

Ecolab's Synergex Sanitizer & Disinfectant Gets First EPA Nod

by Zacks Equity Research

Ecolab's (ECL) Synergex Santizer & Disinfectant becomes the first product to receive U.S. EPA for efficacy against biofilms.

McKesson Extends Partnership With CDC to Fight Coronavirus

by Zacks Equity Research

McKesson (MCK) extends partnership with the CDC to aid in the distribution of future COVID-19 vaccines.

Here's Why You Should Hold on to Intuitive Surgical Stock Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to benefit from rising da Vinci Surgical System, strong international presence and robust recurring revenue base.

Baxter (BAX) Receives EUA for Regiocit Replacement Solution

by Zacks Equity Research

Baxter (BAX) receives EUA from the FDA for Regiocit, which is the only authorized citrate-based replacement solution for use in CRRT during the COVID-19 pandemic.

Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected (Revised)

by Zacks Equity Research

Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q4 earnings as patients avoid hospitals.

Is West Pharmaceutical Services (WST) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (WST) Outperforming Other Medical Stocks This Year?

Myriad Genetics' (MYGN) Q4 Loss Narrower Than Estimated

by Zacks Equity Research

Myriad Genetics (MYGN) sales in each of the operating segments plummet in the quarter owing to the full-quarter adverse impact of the pandemic.

Here's Why You Should Hold on to Stryker (SYK) Stock Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.

Sweta Killa headshot

5 Top-Ranked Stocks Driving ETF as S&P 500 Nears New Highs

by Sweta Killa

Though most stocks in the fund's portfolio are in the green this year, we have highlighted five that are leading the way in the ETF and have a Zacks Rank #2, suggesting their continued outperformance.

Change Healthcare (CHNG) Gains 1.9% Since Q1 Earnings Beat

by Zacks Equity Research

Change Healthcare's (CHNG) fiscal first-quarter results benefit from solid performance across the Network Solutions segment and lower operating expenses.

National Vision (EYE) Stock on the Rise Since Q2 Earnings Beat

by Zacks Equity Research

Investors seem to be impressed with National Vision's (EYE) better-than-expected second-quarter 2020 results despite the coronavirus-led economic crisis.

Glaukos (GKOS) Loses 17.1% Despite Q2 Earnings & Revenues Beat

by Zacks Equity Research

Glaukos' (GKOS) second-quarter results reflect fall in revenues partially mitigated by contribution from Avedro buyout.

Syneos Health (SYNH) Q2 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Syneos Health (SYNH) wins 35 COVID-19 related projects through the second quarter.

Integra (IART) Q2 Earnings Surpass Estimates, Margins Fall

by Zacks Equity Research

Integra's (IART) second-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.

Insulet (PODD) Q2 Earnings Beat Estimates, 2020 View Up

by Zacks Equity Research

Insulet's (PODD) total Omnipod product line comes up with record revenue growth.